BACKGROUND: Local treatment of pelvic Ewing's sarcoma may be challenging, and intergroup studies have focused on improving systemic treatments rather than prospectively evaluating aspects of local tumor control. The Euro-EWING99 trial provided a substantial number of patients with localized pelvic tumors treated with the same chemotherapy protocol. Because local control included surgical resection, radiation therapy, or a combination of both, we wanted to investigate local control and survival with respect to the local modality in this study cohort. QUESTIONS/PURPOSES: (1) Do patients with localized sacral tumors have a lower risk of local recurrence and higher survival compared with patients with localized tumors of the innominate bones? (2) Is the local treatment modality associated with local control and survival in patients with sacral and nonsacral tumors? (3) Which local tumor- and treatment-related factors, such as response to neoadjuvant chemotherapy, institution where the biopsy was performed, and surgical complications, are associated with local recurrence and patient survival in nonsacral tumors? (4) Which factors, such as persistent extraosseous tumor growth after chemotherapy or extent of bony resection, are independently associated with overall survival in patients with bone tumors undergoing surgical treatment? METHODS: Between 1998 and 2009, 1411 patients with previously untreated, histologically confirmed Ewing's sarcoma were registered in the German Society for Pediatric Oncology and Hematology Ewing's sarcoma database and treated in the Euro-EWING99 trial. In all, 24% (339 of 1411) of these patients presented with a pelvic primary sarcoma, 47% (159 of 339) of which had macroscopic metastases at diagnosis and were excluded from this analysis. The data from the remaining 180 patients were reviewed retrospectively, based on follow-up data as of July 2016. The median (range) follow-up was 54 months (5 to 191) for all patients and 84 months (11 to 191) for surviving patients. The study endpoints were overall survival, local recurrence and event-free survival probability, which were calculated with the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) with their respective 95% CIs were estimated in a multivariate Cox regression model. RESULTS: Sacral tumors were associated with a reduced probability of local recurrence (12% [95% CI 1 to 22] versus 28% [95% CI 20 to 36] at 5 years, p = 0.032), a higher event-free survival probability (66% [95% CI 51 to 81] versus 50% [95% CI 41 to 58] at 5 years, p = 0.026) and a higher overall survival probability (72% [95% CI 57 to 87] versus 56% [95% CI 47 to 64] at 5 years, p = 0.025) compared with nonsacral tumors. With the numbers available, we found no differences between patients with sacral tumors who underwent definitive radiotherapy and those who underwent combined surgery and radiotherapy in terms of local recurrence (17% [95% CI 0 to 34] versus 0% [95% CI 0 to 20] at 5 years, p = 0.125) and overall survival probability (73% [95% CI 52 to 94] versus 78% [95% CI 56 to 99] at 5 years, p = 0.764). In nonsacral tumors, combined local treatment was associated with a lower local recurrence probability (14% [95% CI 5 to 23] versus 33% [95% CI 19 to 47] at 5 years, p = 0.015) and a higher overall survival probability (72% [95% CI 61 to 83] versus 47% [95% CI 33 to 62] at 5 years, p = 0.024) compared with surgery alone. Even in a subgroup of patients with wide surgical margins and a good histologic response to induction treatment, the combined local treatment was associated with a higher overall survival probability (87% [95% CI 74 to 100] versus 51% [95% CI 33 to 69] at 5 years, p = 0.009), compared with surgery alone.A poor histologic response to induction chemotherapy in nonsacral tumors (39% [95% CI 19 to 59] versus 64% [95% CI 52 to 76] at 5 years, p = 0.014) and the development of surgical complications after tumor resection (35% [95% CI 11 to 59] versus 68% [95% CI 58 to 78] at 5 years, p = 0.004) were associated with a lower overall survival probability in nonsacral tumors, while a tumor biopsy performed at the same institution where the tumor resection was performed was associated with lower local recurrence probability (14% [95% CI 4 to 24] versus 32% [95% CI 16 to 48] at 5 years, p = 0.035), respectively.In patients with bone tumors who underwent surgical treatment, we found that after controlling for tumor localization in the pelvis, tumor volume, and surgical margin status, patients who did not undergo complete (defined as a Type I/II resection for iliac bone tumors, a Type II/III resection for pubic bone and ischium tumors and a Type I/II/III resection for tumors involving the acetabulum, according to the Enneking classification) removal of the affected bone (HR 5.04 [95% CI 2.07 to 12.24]; p < 0.001), patients with a poor histologic response to induction chemotherapy (HR 3.72 [95% CI 1.51 to 9.21]; p = 0.004), and patients who did not receive additional radiotherapy (HR 4.34 [95% CI 1.71 to 11.05]; p = 0.002) had a higher risk of death. The analysis suggested that the same might be the case in patients with a persistent extraosseous tumor extension after induction chemotherapy (HR 4.61 [95% CI 1.03 to 20.67]; p = 0.046), although the wide CIs pointing at a possible sparse-data bias precluded any definitive conclusions. CONCLUSION: Patients with sacral Ewing's sarcoma appear to have a lower probability for local recurrence and a higher overall survival probability compared with patients with tumors of the innominate bones. Our results seem to support a recent recommendation of the Scandinavian Sarcoma Group to locally treat most sacral Ewing's sarcomas with definitive radiotherapy. Combined surgical resection and radiotherapy appear to be associated with a higher overall survival probability in nonsacral tumors compared with surgery alone, even in patients with a wide resection and a good histologic response to neoadjuvant chemotherapy. Complete removal of the involved bone, as defined above, in patients with nonsacral tumors may be associated with a decreased likelihood of local recurrence and improved overall survival. Persistent extraosseous tumor growth after induction treatment in patients with nonsacral bone tumors undergoing surgical treatment might be an important indicator of poorer overall survival probability, but the possibility of sparse-data bias in our cohort means that this factor should first be validated in future studies. LEVEL OF EVIDENCE: Level III, therapeutic study.

A Leithner Department of Orthopedic Surgery Medical University of Graz Graz Austria

A Ranft U Dirksen Pediatrics 3 Hematology Oncology West German Cancer Center University Hospital Essen Essen Germany

B Timmermann Clinic for Particle Therapy West German Proton Therapy Center University Hospital Essen Essen Germany

D Andreou G Gosheger Department of General Orthopedics and Tumor Orthopedics University Hospital Münster Westfälische Wilhelms University Münster Germany

D Baumhoer Bone Tumor Reference Center Institute of Pathology University Hospital Basel University of Basel Basel Switzerland

H Gelderblom Department of Medical Oncology Leiden University Medical Center Leiden the Netherlands

H Jürgens Department of Paediatric Hematology and Oncology University Hospital Münster Westfälische Wilhelms University Münster Germany

H R Dürr Orthopedic Oncology Department of Orthopedics Ludwig Maximilians University Munich Campus Grosshadern Munich Germany

H van den Berg Department of Pediatric Oncology Emma Children's Hospital Academic Medical Center University of Amsterdam Amsterdam the Netherlands

J Hardes A Streitbürger Department of Tumor Orthopedics and Sarcoma Surgery University Hospital Essen Essen Germany

J Kreyer Department of Orthopedic and Trauma Surgery University Hospital Essen University of Duisburg Essen Essen Germany

J Kruseova Department of Pediatric Hematology and Oncology 2nd Medical School Charles University Prague Prague Czech Republic

L Hjorth Department of Paediatrics Skane University Hospital Clinical Sciences Lund University Lund Sweden

P D S Dijkstra Department of Orthopedic Surgery Leiden University Medical Center Leiden the Netherlands

P U Tunn Department of Orthopedic Oncology HELIOS Klinikum Berlin Buch Berlin Germany

R Ladenstein Department of Studies and Statistics on Integrated Research and Projects Children's Cancer Research Institute Vienna Austria

R Windhager Department of Orthopedics Medical University of Vienna Vienna Austria

S Bauer Department of Medical Oncology Sarcoma Center West German Cancer Center University Hospital Essen University of Duisburg Essen Essen Germany

S Scobioala Department of Radiation Oncology University Hospital Münster Westfälische Wilhelms University Münster Germany

W Hartmann E Wardelmann Gerhard Domagk Institute for Pathology University Hospital Münster Westfälische Wilhelms University Münster Germany

Clin Orthop Relat Res. 2020 Feb;478(2):303-305. doi: 10.1097/CORR.0000000000001097. PubMed

Zobrazit více v PubMed

Abudu A, Davies AM, Pynsent PB, Mangham DC, Tillman RM, Carter SR, Grimer RJ. Tumour volume as a predictor of necrosis after chemotherapy in Ewing's sarcoma. J Bone Joint Surg Br. 1999;81:317-322. PubMed

Andreou D, Bielack SS, Carrle D, Kevric M, Kotz R, Winkelmann W, Jundt G, Werner M, Fehlberg S, Kager L, Kuhne T, Lang S, Dominkus M, Exner GU, Hardes J, Hillmann A, Ewerbeck V, Heise U, Reichardt P, Tunn PU. The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann Oncol. 2011;22:1228-1235. PubMed

Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, Juergens H. Ewing's sarcoma family of tumors: current management. Oncologist. 2006;11:503-519. PubMed

Donaldson SS, Torrey M, Link MP, Glicksman A, Gilula L, Laurie F, Manning J, Neff J, Reinus W, Thompson E, Shuster JJ. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:125-135. PubMed

Donati D, Yin J, Di Bella C, Colangeli M, Bacci G, Ferrari S, Bertoni F, Barbieri E, Mercuri M. Local and distant control in non-metastatic pelvic Ewing's sarcoma patients. J Surg Oncol. 2007;96:19-25. PubMed

Enneking WF, Dunham WK. Resection and reconstruction for primary neoplasms involving the innominate bone. J Bone Joint Surg Am. 1978;60:731-746. PubMed

ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;(25 Suppl 3):iii113-123. PubMed

Fizazi K, Dohollou N, Blay JY, Guerin S, Le Cesne A, Andre F, Pouillart P, Tursz T, Nguyen BB. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol. 1998;16:3736-3743. PubMed

Foulon S, Brennan B, Gaspar N, Dirksen U, Jeys L, Cassoni A, Claude L, Seddon B, Marec-Berard P, Whelan J, Paulussen M, Streitbuerger A, Oberlin O, Juergens H, Grimer R, Le Deley MC. Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. Eur J Cancer. 2016;61:128-136. PubMed

Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, Delattre O, Paulussen M, Picci P, Sundby Hall K, van den Berg H, Ladenstein R, Michon J, Hjorth L, Judson I, Luksch R, Bernstein ML, Marec-Berard P, Brennan B, Craft AW, Womer RB, Juergens H, Oberlin O. Ewing sarcoma: Current management and future approaches through collaboration. J Clin Oncol. 2015;33:3036-3046. PubMed

Gerrand C, Athanasou N, Brennan B, Grimer R, Judson I, Morland B, Peake D, Seddon B, Whelan J, British Sarcoma Group. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016;6:7. PubMed PMC

Greenland S, Mansournia MA, Altman DG. Sparse data bias: a problem hiding in plain sight. BMJ. 2016;352:i1981. PubMed

Hense HW, Ahrens S, Paulussen M, Lehnert M, Jurgens H. Factors associated with tumor volume and primary metastases in Ewing tumors: results from the (EI)CESS studies. Ann Oncol. 1999;10:1073-1077. PubMed

Hesla AC, Tsagozis P, Jebsen N, Zaikova O, Bauer H, Brosjo O. Improved prognosis for patients with Ewing sarcoma in the sacrum compared with the innominate bones: The Scandinavian Sarcoma Group experience. J Bone Joint Surg Am. 2016;98:199-210. PubMed

Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251:166-174. PubMed

Indelicato DJ, Keole SR, Shahlaee AH, Shi W, Morris CG, Gibbs CP, Jr., Scarborough MT, Marcus RB., Jr. Impact of local management on long-term outcomes in Ewing tumors of the pelvis and sacral bones: the University of Florida experience. Int J Radiat Oncol Biol Phys. 2008;72:41-48. PubMed

Indelicato DJ, Keole SR, Shahlaee AH, Shi W, Morris CG, Marcus RB., Jr Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys. 2008;72:871-877. PubMed

Juergens H, Craft A, Lewis I, Oberlin O, Gadner H, Judson I, Paulussen M. EURO-E.W.I.N.G. 99 (European Ewing tumour Working Initiative of National Groups). Ewing tumour studies 1999. Study manual. Amended Version 14th February 2006 Available at: https://www.skion.nl/workspace/uploads/ee99_amended_treo__2006_02_14.pdf. Accessed April 16, 2019.

Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jurgens H. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28:3284-3291. PubMed

Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, Le Teuff G, Michon J, Ladenstein R, Marec-Berard P, van den Berg H, Hjorth L, Wheatley K, Judson I, Juergens H, Craft A, Oberlin O, Dirksen U. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol. 2014;32:2440-2448. PubMed

Lee J, Hoang BH, Ziogas A, Zell JA. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer. 2010;116:1964-1973. PubMed

Leopold SS, Porcher R. Editorial: Sparse-data bias--What the savvy reader needs to know. Clin Orthop Relat Res. 2018;476:657-659. PubMed PMC

Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am. 1996;78:656-663. PubMed

Ng VY, Jones R, Bompadre V, Louie P, Punt S, Conrad EU., 3rd The effect of surgery with radiation on pelvic Ewing sarcoma survival. J Surg Oncol. 2015;112:861-865. PubMed

Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Amann G, Dockhorn-Dworniczak B, Harms D, Muller-Weihrich S, Welte K, Kornhuber B, Janka-Schaub G, Gobel U, Treuner J, Voute PA, Zoubek A, Gadner H, Jurgens H. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol. 2001;19:1818-1829. PubMed

Werier J, Yao X, Caudrelier JM, Di Primio G, Ghert M, Gupta AA, Kandel R, Verma S. A systematic review of optimal treatment strategies for localized Ewing's sarcoma of bone after neo-adjuvant chemotherapy. Surg Oncol. 2016;25:16-23. PubMed

Whelan J, Le Deley MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N, Hawkins DS, Amler S, Bauer S, Bielack S, Blay JY, Burdach S, Castex MP, Dilloo D, Eggert A, Gelderblom H, Gentet JC, Hartmann W, Hassenpflug WA, Hjorth L, Jimenez M, Klingebiel T, Kontny U, Kruseova J, Ladenstein R, Laurence V, Lervat C, Marec-Berard P, Marreaud S, Michon J, Morland B, Paulussen M, Ranft A, Reichardt P, van den Berg H, Wheatley K, Judson I, Lewis I, Craft A, Juergens H, Oberlin O, Euro EWING, Investigators E- High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018:JCO2018782516. PubMed PMC

Yang RS, Eckardt JJ, Eilber FR, Rosen G, Forscher CA, Dorey FJ, Kelly CM, al-Shaikh R. Surgical indications for Ewing's sarcoma of the pelvis. Cancer. 1995;76:1388-1397. PubMed

Yock TI, Krailo M, Fryer CJ, Donaldson SS, Miser JS, Chen Z, Bernstein M, Laurie F, Gebhardt MC, Grier HE, Tarbell NJ, Children's Oncology G. Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. J Clin Oncol. 2006;24:3838-3843. PubMed

Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum

Effect of Radiotherapy Dose on Outcome in Nonmetastatic Ewing Sarcoma